St Jude Medical gains approval for cardiac resynchronisation therapy defibrillator

Quadra Assura MP CRT-D gives medics more choices to best optimise and tailor cardiac resynchronisation pacing

St Jude Medical has gained CE mark approval for its next-generation quadripolar device, the Quadra Assura MP cardiac resynchronisation therapy defibrillator (CRT-D).

The Quadra Assura MP CRT-D features MultiPoint Pacing (MPP) technology that enables physicians to pace multiple locations simultaneously or sequentially on the left side of the heart, rather than the standard single pacing pulse. This gives the clinician more choices to best optimise and tailor cardiac resynchronisation therapy (CRT) pacing to meet individual patient needs.

Preliminary results from a study presented at this year’s Heart Rhythm Society (HRS) Scientific Sessions showed that after three months, 89% of patients treated with the MPP device were classified as responders, an increase of nearly 20%. On average, the response rate to traditional CRT is approximately 70%.

Companies